Neumora Therapeutics (NMRA) Research & Development (2022 - 2026)
Neumora Therapeutics (NMRA) posted Research & Development of $29.28 million for Q2 2026, down 24.4% from $38.72 million a year earlier and down 24.1% from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Research & Development (2022 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Neumora Therapeutics was $153.07 million, down 22.5% year-over-year; for FY2025, it was $176.07 million, down 12.4% from FY2024.
- Annual Research & Development shows a three-year compound annual growth rate of 24.3% (FY2022 to FY2025).
- In prior years, Neumora Therapeutics' Research & Development was $200.93 million in FY2024 (+40.8%), $142.72 million in FY2023 (+55.6%) and $91.75 million in FY2022.
- The Q2 2026 figure stands as the lowest quarterly Research & Development since Q4 2022.
- On a year-over-year basis, Research & Development has declined in each of the last five quarters, with an average decline of 3.6% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was Q3 2023, with growth of 84.5%; the weakest was Q3 2025, with a decline of 33.2%.
- According to Business Quant data, Research & Development for the three prior quarters was $38.6 million (Q1 2026), $44.67 million (Q4 2025) and $40.52 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Neumora Therapeutics | 88.31 Mn | -529.65 Mn | - | 29.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.28 Mn |
| Mar 31, 2026 | 38.60 Mn |
| Dec 31, 2025 | 44.67 Mn |
| Sep 30, 2025 | 40.52 Mn |
| Jun 30, 2025 | 38.72 Mn |
| Mar 31, 2025 | 52.15 Mn |
| Dec 31, 2024 | 45.91 Mn |
| Sep 30, 2024 | 60.63 Mn |
| Jun 30, 2024 | 48.63 Mn |
| Mar 31, 2024 | 45.76 Mn |
| Dec 31, 2023 | 38.86 Mn |
| Sep 30, 2023 | 41.60 Mn |
| Jun 30, 2023 | 32.77 Mn |
| Mar 31, 2023 | 29.49 Mn |
| Dec 31, 2022 | 23.52 Mn |
| Sep 30, 2022 | 22.55 Mn |
API Access
Neumora Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();